Search
Showing results for "early lung health"
More than 30 years of research into the links between folate and neural tube defects has paid off for The Kids Research Institute Australia researcher Professor Carol Bower.
As a new parent or parent-to-be, you will be faced with many important decisions about your health and the health of your child, including immunisation.
It is now well accepted that germline or de novo genetic alterations predispose to cancer development, especially during childhood. Among them, constitutive trisomy 21, also known as Down syndrome (DS), has been shown to predispose to acute leukemia affecting both the myeloid (ML-DS) and lymphoid (DS-ALL) lineages. ML-DS is associated with a good prognosis compared to children without DS, due in part to a higher sensitivity to conventional chemotherapy.
Extensive research over the past 50 years has resulted in significant improvements in survival for patients diagnosed with leukemia. Despite this, a subgroup of patients harboring high-risk genetic alterations still suffer from poor outcomes. There is a desperate need for new treatments to improve survival, yet consistent failure exists in the translation of in vitro drug development to clinical application.
Meet Rachelle Ward one of our Consumer Representatives
Re: Recommendations from the Diabetes and Endocrinology Department at Perth Children’s Hospital and the Children’s Diabetes Centre at The Kids Research Institute Australia regarding COVID-19 vaccination for children with diabetes
Kids with diabetes should think beyond just carbs, according to The Kids Research Institute Australia senior dietitian Dr Amelia Harray.
Patients require on average about 50 per cent more insulin with a high protein meal than with a low protein meal. A study conducted by the Children's Diabetes Centre used an insulin clamp technique to determine insulin requirements to maintain euglycaemia across the different meals.
The Wesfarmers Centre is pleased to announce the 4 successful applications for the 2016 Round 1 Wesfarmers Centre Seed Funding.
Allogeneic hematopoietic stem cell transplant (HSCT) is a proven curative therapy for children with high-risk myeloid malignancies. Disease relapse, transplant-related mortality and graft versus host disease (GvHD) are the main causes of treatment failure and death post-transplant. The optimum pretransplant conditioning regimen is yet to be defined. There is limited data regarding the use of busulfan, fludarabine and melphalan as a myeloablative conditioning regimen in children receiving HSCT for myeloid malignancies.